Literature DB >> 1832291

Hormonal effects of the diuretic xipamide in healthy men.

P Lijnen1, R Fagard, J Staessen, A Amery.   

Abstract

The effect of xipamide on plasma alpha-atrial natriuretic peptide and the renin-aldosterone-kallikrein system have been studied in 12 healthy men, using a double-blind cross-over design. After a run-in period on placebo of 1 week, the subjects were treated with either placebo (n = 6) or xipamide 20 mg once daily (n = 6) for 16 weeks and were then switched to the alternative medication for another 16 weeks. The plasma concentration of alpha-atrial natriuretic peptide fell after 1 week of xipamide administration and increased during prolonged xipamide administration but remained reduced. The changes in plasma alpha-ANP observed after 1 week of xipamide were negatively correlated with the changes in hematocrit and hemoglobin. Plasma renin activity (PRA), aldosterone concentration (PAC), and urinary excretion of aldosterone and kallikrein increased after 1 week of xipamide administration, levelled off during the second and fourth weeks, but remained elevated during further prolonged xipamide administration for 16 weeks. The xipamide-induced changes in PRA and PAC were positively correlated with the changes in the hematocrit and hemoglobin. The changes in plasma renin, aldosterone, and alpha-atrial natriuretic peptide during xipamide administration may be related to diuretic-induced volume contraction.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1832291     DOI: 10.1007/bf03029749

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  15 in total

1.  Methodological simplifications in radioimmunoassay of urinary aldosterone.

Authors:  R Malvano; S Orlandini; P Cozzani; P Duranti; N Simonini; A Salvetti
Journal:  Clin Chim Acta       Date:  1976-02-02       Impact factor: 3.786

2.  Vasoconstriction-volume analysis for understanding and treating hypertension: the use of renin and aldosterone profiles.

Authors:  J H Laragh
Journal:  Am J Med       Date:  1973-09       Impact factor: 4.965

3.  Renin-angiotensin-aldosterone system during chronic thiazide therapy of benign hypertension.

Authors:  J J Bourgoignie; F J Catanzaro; H M Perry
Journal:  Circulation       Date:  1968-01       Impact factor: 29.690

4.  The two-period cross-over clinical trial.

Authors:  M Hills; P Armitage
Journal:  Br J Clin Pharmacol       Date:  1979-07       Impact factor: 4.335

Review 5.  Diuretics in hypertension.

Authors:  E D Frohlich
Journal:  J Hypertens Suppl       Date:  1987-08

6.  Direct radioimmunoassay of plasma aldosterone in normal subjects.

Authors:  P Lijnen; A Amery; R Fagard; P Corvol
Journal:  Clin Chim Acta       Date:  1978-03-15       Impact factor: 3.786

7.  Faster radioimmunoassay of angiotensin I at 37 degrees C.

Authors:  F Fyhrquist; L Puutula
Journal:  Clin Chem       Date:  1978-01       Impact factor: 8.327

8.  Decreased urinary kallikrein activity and elevated blood pressure normalized by orally applied kallikrein in essential hypertension.

Authors:  A Overlack; K O Stumpe; C Ressel; R Kolloch; W Zywzok; F Krück
Journal:  Klin Wochenschr       Date:  1980-01-02

9.  Hemodynamic changes during long-term thiazide treatment of essential hypertension in responders and nonresponders.

Authors:  P van Brummelen; A J Man in 't Veld; M A Schalekamp
Journal:  Clin Pharmacol Ther       Date:  1980-03       Impact factor: 6.875

Review 10.  Xipamide. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy.

Authors:  B N Prichard; R N Brogden
Journal:  Drugs       Date:  1985-10       Impact factor: 9.546

View more
  1 in total

Review 1.  Central hemodynamic effects of diuretic therapy in chronic heart failure.

Authors:  B Silke
Journal:  Cardiovasc Drugs Ther       Date:  1993-01       Impact factor: 3.727

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.